Sign In
Buy CERE
$44.96
+0 (+0%)
At Close: Oct 30, 2024
Cramer reacts to AbbVie buying Cerevel Therapeutics
01:02pm, Thursday, 07'th Dec 2023
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) jumped some 12% today after AbbVie Inc (NYSE: ABBV) said it will buy the drug company that focuses primarily on neurological disorders. AbbVie seems to
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion
10:50am, Thursday, 07'th Dec 2023
CNBC's David Faber delivers his latest Faber Report.
AbbVie to acquire drugmaker Cerevel Therapeutics for $8.7B
10:24am, Thursday, 07'th Dec 2023
AbbVie Inc announced late Wednesday an agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $45 per share in cash, or a total equity value of approximately $8.7 billion. Cerevel's
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout
09:51am, Thursday, 07'th Dec 2023
U.S. drugmaker Abbvie said on Thursday it does not expect any transactions similar to its $8.7 billion buyout of Cerevel Therapeutics in the foreseeable future and would instead focus on smaller deals
Why Is Cerevel Therapeutics (CERE) Stock Up 12% Today?
09:45am, Thursday, 07'th Dec 2023
Cerevel Therapeutics (NASDAQ: CERE ) stock is on the rise Thursday after the clinical-stage biopharmaceutical company reached an acquisition deal with AbbVie (NYSE: ABBV ). That deal has AbbVie agreei
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
06:46am, Thursday, 07'th Dec 2023
AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.
Shareholder Alert: Ademi LLP investigates whether Cerevel Therapeutics has obtained a Fair Price in its transaction with AbbVie
11:52pm, Wednesday, 06'th Dec 2023
MILWAUKEE , Dec. 6, 2023 /PRNewswire/ -- Ademi LLP is investigating Cerevel (NASDAQ: CERE) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie. Click her
NEW YORK , Dec. 6, 2023 /PRNewswire/ -- Julie & Holleman LLP, a nationally recognized shareholder rights law firm, is investigating the proposed $45 per share sale of Cerevel Therapeutics Holdings, I
Cerevel options trading surge before AbbVie deal news raises eyebrows
10:33pm, Wednesday, 06'th Dec 2023
Trading in the options of Cerevel Therapeutics Holdings Inc experienced an unusual surge along with its stock price in the days before Wednesday's announcement that AbbVie would buy the drug developer
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders
07:33pm, Wednesday, 06'th Dec 2023
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. for $45.00 per share in
AbbVie to buy drug developer Cerevel for $8.7 billion
06:24pm, Wednesday, 06'th Dec 2023
AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its huge-selling arthritis drug Hum
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion
05:06pm, Wednesday, 06'th Dec 2023
The deal is AbbVie's latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic competition.
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson's Disease
06:30am, Wednesday, 29'th Nov 2023
Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson's disease
3 Biotech Stocks That Could Boom or Bust by 2025
05:35pm, Thursday, 16'th Nov 2023
InvestorPlace published an article last December about the seven hottest biotech stocks to own in 2023 and beyond. One of the seven was the SPDR S&P Biotech ETF (NYSEARCA: XBI ).
Cerevel Therapeutics to Present at Upcoming Investor Conferences
06:30am, Wednesday, 08'th Nov 2023
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced
